Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 433

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 433
---
 Date, we
are required to (i) facilitate an introduction between the Licensee and the Gloperba CMO as of the Effective Date, and (ii) use reasonable efforts to cause such Gloperba CMO to accept a direct engagement with the Licensee for the
manufacturing or supply of the Gloperba Product in finished dosage form. In addition, we agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba License
Term.

The Gloperba License Term commences on the Effective Date and continues until expiration of the last to expire Licensed Patents (as
defined therein), unless earlier terminated.

The foregoing summary of the Gloperba License Agreement does not purport to be complete and
is qualified in its entirety by reference to the full text of the Gloperba License Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part.

Consent, Waiver and Amendment

On
April 16, 2025, in connection with the formation of Scilex Bio, Inc. the Company entered into a Consent, Waiver and Amendment re Tranche A Senior Secured Promissory Note with Oramed (the “Oramed Consent and Waiver”), pursuant to
which certain definitions in the Oramed Note were modified to reflect, among other things, that Scilex Bio will not be deemed a subsidiary of Scilex under the terms of the Oramed Note.

The above descriptions of the Oramed Consent and Waiver is not complete and is qualified in its entirety by reference to the full text of the
Oramed Consent and Waiver, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part.

Oramed Penny Warrant Repurchase

As previously disclosed and as described elsewhere in this prospectus, on September 21, 2023, the Company
issued Penny Warrants to purchase up to an aggregate of 6,500,000 shares of Common Stock to Oramed.

On July 22, 2025, the Company
entered into the Option Agreement with Oramed, pursuant to which, among other things, Oramed granted the Option to the Company to repurchase the Penny Warrants in two tranches for an aggregate purchase price of $27,000,000, subject to the terms and
conditions set forth therein. In consideration of the